{"id":"antibody-drug-conjugate-chemotherapeutic","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4298033","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism involves the use of monoclonal antibodies that are engineered to bind to a specific protein on the surface of cancer cells. Once bound, the antibody is internalized by the cell, releasing a toxic payload that kills the cell.","oneSentence":"Antibody drug conjugates target specific cancer cells by binding to a protein on the cell surface and delivering a toxic payload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:32.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06956690","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors","status":"RECRUITING","sponsor":"Hummingbird Bioscience","startDate":"2025-12-17","conditions":"Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer","enrollment":180},{"nctId":"NCT04644068","phase":"PHASE1, PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Ovarian Cancer, Breast Cancer, Pancreatic Cancer","enrollment":702},{"nctId":"NCT04965766","phase":"PHASE2","title":"Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2021-05-11","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":139},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT06121557","phase":"PHASE1","title":"Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-01","conditions":"Breast Neoplasms","enrollment":24},{"nctId":"NCT02631876","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"ImmunoGen, Inc.","startDate":"2016-03-02","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":366},{"nctId":"NCT02312037","phase":"","title":"Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"CD33 Positive Acute Myelogenous Leukemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":378,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemtuzumab ozogamicin"],"phase":"phase_2","status":"active","brandName":"Antibody Drug Conjugate Chemotherapeutic","genericName":"Antibody Drug Conjugate Chemotherapeutic","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Antibody drug conjugates target specific cancer cells by binding to a protein on the cell surface and delivering a toxic payload. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}